Research Analysis of Altimmune, Inc. (NASDAQ:ALT)

Altimmune, Inc. (ALT) belonging to the Healthcare sector has declined -1.25% and closed its last trading session at $0.4.

The company reported its EPS on 3/30/2018. Currently, the stock has a 1 Year Price Target of $4.

The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 0 and 1 respectively.

Many analysts have provided their estimated foresights on Altimmune, Inc. Earnings, with 1 analysts believing the company would generate an Average Estimate of $-0.15.

Whereas they predicted High and Low Earnings Estimate as $-0.15 and $-0.15 respectively.

Analysts are also projecting an Average Revenue Estimate for Altimmune, Inc. as $3010 in the Current Quarter. This estimate is provided by 1 analysts.

Altimmune, Inc. (ALT) has the market capitalization of $13.83 Million. The company rocked its 52-Week High of $3.16 and touched its 52-Week Low of $0.333.

The stock has Return on Assets (ROA) of -71.6 percent. Return on Equity (ROE) stands at -101% and Return on Investment (ROI) of -114.9 percent.

The stock is currently showing YTD performance of -80.15 Percent. The company has Beta Value of 2.38 and ATR value of 0.06. The Weekly and Monthly Volatility stands at 15.69% and 14.92%.